NitroMed lays off researchers in shakeup
Reeling from low sales of its newly-approved heart drug BiDil, NitroMed has announced it is laying off 30 researchers and is looking for partners for other experimental heart therapies in its pipeline. The Lexington, MA-based company's CEO and CFO had already been let go earlier this month, and NitroMed is focusing its efforts on gearing up sales of BiDil. About 150 contract sales people are being made full time employees.
- read the Boston Herald report
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
